Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + tremelimumab + lenvatinib as first-line treatment for unresectable hepatocellular carcinoma
CTR20252535Phase 2Active
- Sponsor
- MedImmune
- Start
- Aug 2025
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tiragolumab, lenvatinib in hepatocellular carcinoma (HCC), sponsored by MedImmune. Started Aug 2025; status: active.
02
Drugs
durvalumabtiragolumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20252535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252535.